Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shot up 4.2% during mid-day trading on Wednesday . The company traded as high as $52.90 and last traded at $52.69, with a volume of 221,368 shares. The stock had previously closed at $50.55.

A number of brokerages recently issued reports on RARE. Jefferies Group reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Sunday. Canaccord Genuity reissued a “buy” rating and set a $120.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, July 15th. Credit Suisse Group AG reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 12th. Wedbush reaffirmed an “outperform” rating and issued a $92.00 price target (down previously from $99.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Finally, Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. Three investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Ultragenyx Pharmaceutical has a consensus rating of “Buy” and a consensus target price of $98.09.

The firm’s 50-day moving average price is $57.37 and its 200 day moving average price is $63.91. The stock’s market cap is $2.06 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.29) by $0.06. During the same quarter in the previous year, the company earned ($0.63) earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($5.84) earnings per share for the current year.

In related news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $50.85, for a total value of $1,017,000.00. Following the transaction, the chief executive officer now owns 513,597 shares of the company’s stock, valued at $26,116,407.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Sunil Agarwal sold 650 shares of the stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $66.00, for a total value of $42,900.00. Following the completion of the transaction, the insider now directly owns 7,111 shares in the company, valued at approximately $469,326. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in RARE. Trexquant Investment LP purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $1,010,000. Wells Fargo & Company MN boosted its position in shares of Ultragenyx Pharmaceutical by 14.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,774,736 shares of the biopharmaceutical company’s stock valued at $199,090,000 after buying an additional 219,746 shares during the period. Mutual of America Capital Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 33,497 shares of the biopharmaceutical company’s stock valued at $3,758,000 after buying an additional 497 shares during the period. GSA Capital Partners LLP boosted its position in shares of Ultragenyx Pharmaceutical by 12.2% in the fourth quarter. GSA Capital Partners LLP now owns 11,188 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 1,218 shares during the period. Finally, GAM Holding AG boosted its position in shares of Ultragenyx Pharmaceutical by 53.3% in the fourth quarter. GAM Holding AG now owns 32,500 shares of the biopharmaceutical company’s stock valued at $3,646,000 after buying an additional 11,300 shares during the period.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.